#United States #RedHill Biopharma #Oklahoma #CAR T-Cell #Opaganib

Advancing Cancer Treatment: RedHill's New Grant

In a significant development for cancer research, RedHill Biopharma Ltd. announced that its partner, the University of Oklahoma (OU), has secured a grant of $2.9 million from the National Cancer Institute (NCI). This grant will primarily fund clinical trials focusing on the combination of RedHill's investigational drug, opaganib, alongside CAR T-cell therapy, specifically targeting ultra-high-risk multiple myeloma patients.

The Grant and Its Purpose

The five-year funding will encompass two phases of clinical trials. The first phase (Phase 1b) aims to recruit up to 18 patients, with the objective of assessing the safety of the combined treatment approach and determining the optimal dose of opaganib. Following this, a Phase 2 trial will expand participation to an additional 21 patients to gather preliminary evidence regarding the effectiveness of the treatment.

CAR T-cell therapy is a revolutionary method wherein a patient’s own immune cells are genetically modified to better recognize and combat cancer cells. This innovative approach will mark a first for Oklahoma, as the CAR T cells will be manufactured on the OU campus rather than relying on commercial facilities, which is expected to streamline processes and reduce costs.

Challenges in Treating Multiple Myeloma

Despite advances in medical therapies, patients grappling with ultra-high-risk multiple myeloma continue to experience poor outcomes, and the cancer frequently recurs even after treatment options such as bone marrow transplants. Dr. Yubin Kang, the grant awardee and a hematologist-oncologist at OU, emphasizes the urgent need for new treatment strategies. He explains that preclinical studies conducted over the past decade indicate that opaganib could enhance the durability and activity of CAR T-cells, thereby promoting a longer-lasting antitumor response against myeloma.

Opaganib functions by inhibiting a protein known as sphingosine kinase-2 (SPHK2), which is believed to act as an impediment to the immune system's T cells capable of fighting cancer. With previous research indicating that blocking SPHK2 in mouse models leads to enhanced T-cell proliferation and effectiveness against myeloma cells, the researchers are cautiously optimistic.

Insights from RedHill’s Leadership

Dr. Mark Levitt, Chief Scientific Officer at RedHill, remarked, “Opaganib has shown promise as a potential combinatory therapy in various oncological applications.” He reiterated the importance of Dr. Kang’s research and the grant’s potential to bring significant change. The collaborative effort, involving RedHill for providing opaganib and Lentigen Technology Inc. for CAR construct development, exemplifies a united front in combatting this challenging cancer type.

The Research Landscape

The planned clinical trials signify a leap forward in understanding the intricate dynamics between opaganib and CAR T-cell therapy. With both anticipation and hope, researchers await the results that could potentially redefine treatment protocols for high-risk multiple myeloma. The studies will comply with rigorous standards, ensuring the safety and efficacy of the proposed treatments.

In summary, this $2.9 million NCI grant opens up new avenues for innovative cancer treatments, particularly for patients facing ultra-high-risk multiple myeloma. As RedHill Biopharma and its partners navigate this pioneering research phase, the medical community watches closely for developments that could lead to improved patient outcomes and more effective treatment strategies.

Conclusion

In conclusion, the awarded grant not only provides much-needed financial support for intensive research but also serves as a significant step toward enhancing therapeutic options for one of the most challenging forms of cancer. The collaboration underlines a commitment to tackling cancer with groundbreaking scientific approaches, and the future research could pave the way for more successful interventions in the field of oncology.